| Literature DB >> 31597009 |
Piotr J Bachul1, Justyna E Gołębiewska1,2, Lindsay Basto1, Karolina Gołąb1, Roi Anteby1,3, Ling-Jia Wang1, Martin Tibudan1, Celeste Thomas4, Wojciech Fendler5, Aaron Lucander1, Damian J Grybowski1, Alicja Dębska-Ślizień2, John Fung1, Piotr Witkowski1.
Abstract
This study aimed to evaluate whether the BETA-2 score is a reliable early predictor of graft decline and loss of insulin independence after islet allotransplantation. Islet transplant procedures were stratified into 3 groups according to clinical outcome: long-term insulin independence without islet graft decline (group 1, N = 9), initial insulin independence with subsequent islet graft decline and loss of insulin independence (group 2, N = 13), and no insulin independence (group 3, N = 13). BETA-2 was calculated on day 75 and multiple times afterwards for up to 145 months posttransplantation. A BETA-2 score cut-off of 17.4 on day 75 posttransplantation was discerned between group 1 and groups 2 and 3 (area under the receiver operating characteristic 0.769, P = .005) with a sensitivity and negative predictive value of 100%. Additionally, BETA-2 ≥ 17.4 at any timepoint during follow-up reflected islet function required for long-term insulin independence. While BETA-2 did not decline below 17.4 for each of the 9 cases from group 1, the score decreased below 17.4 for all transplants from group 2 with subsequent loss of insulin independence. The reduction of BETA-2 below 17.4 predicted 9 (1.5-21) months in advance subsequent islet graft decline and loss of insulin independence (P = .03). This finding has important implications for posttransplant monitoring and patient care.Entities:
Keywords: clinical research/practice; diabetes: type 1; islet transplantation; islets of Langerhans; quality of care/care delivery
Mesh:
Substances:
Year: 2019 PMID: 31597009 DOI: 10.1111/ajt.15645
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086